Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 17, 2024 12:58 ET | Source: Theriva Biologics, Inc.

Theriva Biologics anuncia el desdoblamiento inverso de sus acciones

ROCKVILLE, Md., Aug. 17, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar enfermedades...
August 16, 2024 16:05 ET | Source: Theriva Biologics, Inc.

Theriva Biologics Announces Reverse Stock Split

ROCKVILLE, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of...
August 13, 2024 15:09 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2024

- Se espera que la inscripción a VIRAGE, el ensayo clínico de Fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma pancreático ductal metastásico (PDAC), finalice en el tercer...
August 13, 2024 08:00 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results

- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), is expected to complete enrollment in the third quarter of...
July 31, 2024 17:32 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics obtiene la designación de fármaco pediátrico poco frecuente por la FDA estadounidense para el VCN-01 para el tratamiento del retinoblastoma

ROCKVILLE, Maryland, July 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el...
July 31, 2024 08:15 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

ROCKVILLE, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related...
May 23, 2024 21:38 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics anuncia la designación de vía rápida concedida por la FDA estadounidense al VCN-01 para el tratamiento del cáncer de páncreas metastásico

ROCKVILLE, Maryland, May 24, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y...
May 23, 2024 08:15 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases...
May 14, 2024 08:00 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics participará en la conferencia virtual de salud de A.G.P.

ROCKVILLE, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), empresa diversificada de fase clínica que investiga tratamientos antineoplásicos y enfermedades...
May 14, 2024 08:00 ET | Source: Theriva Biologics, Inc.

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference

ROCKVILLE, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases...